ABSTRACT
Oxidative distress and inflammation are common biochemical disorders in individuals with cancer. The measurement of oxidative stress in oncology can be useful in clinical practice to monitor the effectiveness of therapy and unwanted effects of the treatment. Thus, the aim of the present study was to evaluate the redox status through the reactive oxygen metabolites (d-ROMs) and biological antioxidant potential (BAP) tests and investigate the correlations of these parameters with blood variables in cancer patients. This is an observational, retrospective study of analysis of medical records of patients evaluated the period from 2018 to 2020 in an integrative medicine center. The inclusion criteria were individuals of both sexes, over 18 years of age, diagnosed with cancer who performed the d-ROMs and BAP test in the same period of blood analysis. Following the inclusion criteria, the final sample of the study were 57 individuals, 60% were woman and 40% were men. The evaluation of redox state showed that the d-ROMs were high (420.2 ± 112.1 U CARR) in total sample and higher in women compared to male (p < 0.01) and BAP tests were normal (2332 ± 812 μmol/l). The oxidative parameters, d-ROMs and OSI, was correlated positively with BAP, red cell distribution width (only d-ROMs), platelets (Plt), C-reactive protein (CRP), erythrocyte sedimentation (ESR) and negatively with hemoglobin (Hb) and mean corpuscular hemoglobin (MCH). Regarding the antioxidant potential index, BAP/dROMs, were correlated positively with Hb and serum albumin (HAS) and negatively correlated with Plt, CRP and ESR. The study shows that redox status of an individual with cancer is altered, and it is possible to monitor this system in clinical practice through d-ROMs and BAP test. These parameters, in addition to being suitable for assessing oxidative stress, were correlated with parameters predictors of inflammation.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NA
Clinical Protocols
https://hedsrl.it/en/d-roms-fast-test/
https://hedsrl.it/en/pat-test/
Funding Statement
Foued Salmen Espíndola is financial supported from Fundação de Amparo à Pesquisa do Estado de Minas Gerais–FAPEMIG [Rede Mineira de Pesquisa Translacional em Imunobiológicos e Biofármacos no âncer (REMITRIBIC, RED-00031-21)] and Programa Pesquisador Mineiro (FAPEMIG-PPM-00503-18). FSE also received scholarship for research productivity from Conselho Nacional Científico e Tecnológico do Brasi-CNPq.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Human Research Ethics Committee (n° 5.671.038/2022) of the UNA University Center.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
